[go: up one dir, main page]

AU2001218866A1 - Preparation for strengthening the immune response in the waldeyer's ring and theoronasal mucosa by intranasal administration - Google Patents

Preparation for strengthening the immune response in the waldeyer's ring and theoronasal mucosa by intranasal administration

Info

Publication number
AU2001218866A1
AU2001218866A1 AU2001218866A AU1886601A AU2001218866A1 AU 2001218866 A1 AU2001218866 A1 AU 2001218866A1 AU 2001218866 A AU2001218866 A AU 2001218866A AU 1886601 A AU1886601 A AU 1886601A AU 2001218866 A1 AU2001218866 A1 AU 2001218866A1
Authority
AU
Australia
Prior art keywords
waldeyer
strengthening
ring
mucosa
glucan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001218866A
Inventor
Luigi Mercuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DMG Italia SRL
Original Assignee
DMG Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DMG Italia SRL filed Critical DMG Italia SRL
Publication of AU2001218866A1 publication Critical patent/AU2001218866A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A product to be administered by nose for preventing inflammatory or hypertrophic forms and strengthening the immune action in the Waldeyer's ring and the oronasal mucosa consists of a physiological action with a high concentration in a polysaccharide such as glucan. In particular, two solutions having different concentrations have been specified, namely a first physiological solution with a glucan concentration equal to 0.25 % for cleaning the nasal fossae and with a preventive hydrating, reepithelializing capability of strengthening the immune action in the Waldeyer's ring and the oronasal mucosa, and a physiological solution with a glucan concentration equal to 2 % for hydrating and reepithelializing the nasal mucosa, capable of strengthening the immune response in the Waldeyer's ring duringthe acute phase of the inflammatory, hypertrophic forms of the same. Glucan is preferably used in the form beta -(1-3)-glucan.
AU2001218866A 2000-11-22 2000-11-22 Preparation for strengthening the immune response in the waldeyer's ring and theoronasal mucosa by intranasal administration Abandoned AU2001218866A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2000/000479 WO2002041900A1 (en) 2000-11-22 2000-11-22 Preparation for strengthening the immune response in the waldeyer's ring and the oronasal mucosa by intranasal administration

Publications (1)

Publication Number Publication Date
AU2001218866A1 true AU2001218866A1 (en) 2002-06-03

Family

ID=11133585

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001218866A Abandoned AU2001218866A1 (en) 2000-11-22 2000-11-22 Preparation for strengthening the immune response in the waldeyer's ring and theoronasal mucosa by intranasal administration

Country Status (7)

Country Link
EP (1) EP1337260B1 (en)
AT (1) ATE290873T1 (en)
AU (1) AU2001218866A1 (en)
DE (1) DE60018812T2 (en)
ES (1) ES2237477T3 (en)
PT (1) PT1337260E (en)
WO (1) WO2002041900A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0225502D0 (en) * 2002-11-01 2002-12-11 Zoolife Internat Ltd Therapeutic and prophylactic preparations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0045718A3 (en) * 1980-07-25 1983-01-19 Ciba-Geigy Ag Nasal compositions and method of preparing them
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5519009A (en) * 1993-10-01 1996-05-21 Donzis; Byron A. Solubilized yeast glucan
FR2780285B1 (en) * 1998-06-29 2001-10-05 Goemar Lab Sa USE OF ISOOSMOTIC SALINE SOLUTIONS, THEIR PREPARATION METHOD AND ANTI-INFLAMMATORY DRUGS BASED ON SUCH SOLUTIONS

Also Published As

Publication number Publication date
PT1337260E (en) 2005-05-31
EP1337260B1 (en) 2005-03-16
DE60018812T2 (en) 2005-08-11
DE60018812D1 (en) 2005-04-21
EP1337260A1 (en) 2003-08-27
WO2002041900A1 (en) 2002-05-30
ES2237477T3 (en) 2005-08-01
ATE290873T1 (en) 2005-04-15

Similar Documents

Publication Publication Date Title
EP1283054A4 (en) Drugs for complications of diabetes and neuropathy and utilization thereof
WO2003024387A3 (en) Method and pharmaceutical composition for treating inflammation
EP0734249A4 (en) Novel and improved aminoglycoside formulation for aerosolization
BR9509590A (en) Application of sod in liposomes
DK1107732T3 (en) Oral liquid mucoadhesive preparations
KR890014088A (en) Compositions used to improve the smoothness of the skin and how to improve their smoothness
CN115607464B (en) Antibacterial stain-removing toothpaste and preparation method thereof
EE03016B1 (en) Oral Formulation for the Treatment of Central Dopamine Deficiency and Method for Its Preparation
AP2002002674A0 (en) Clear Aqueous Anaesthetic composition.
KR920003971A (en) Eye drop composition
SE8602722L (en) SUSTAINABLE ADMINISTRATION FORMS
CA2507926A1 (en) Pharmaceutical composition comprising chito-oligomers
AR015744A1 (en) USE OF DEXMEDETOMIDINE FOR SEDATION IN INTENSIVE THERAPY
DE60221227D1 (en) Xanthan gum-containing reepithelializing pharmaceutical preparations
ATE314068T1 (en) TREATMENT OF SEBORRHOIC DERMATITIS
DE60208528D1 (en) HIGHLY SULFATED DERIVATIVES OF K5 POLYSACCHARIDES AND THEIR PREPARATION
IE891314L (en) Pharmaceutical compositions of 1,5-d1¹(4-amidinophenoxy) pentane
AU2001218866A1 (en) Preparation for strengthening the immune response in the waldeyer's ring and theoronasal mucosa by intranasal administration
CA2236237A1 (en) Use of hyaluronic acid and corresponding salts for the preparation of an aqueous solution useful as intra-articular lavage liquid
WO2015013549A1 (en) Treating oral inflammation, injury or pain
AU1665992A (en) Novel taurine-based pharmaceutical composition for administration by inhalation
WO2004028457A3 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY
CN108652999B (en) A kind of children's toothpaste and preparation method thereof
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
NO965468L (en) Pharmaceutical preparation for the prevention and / or treatment of viral infections and possible inflammations, as well as a method of treatment thereof